Public Health Sciences, University of Edinburgh, Edinburgh, UK.
Int J Epidemiol. 2010 Apr;39 Suppl 1(Suppl 1):i172-85. doi: 10.1093/ije/dyq033.
With the aim of populating the Lives Saved Tool (LiST) with parameters of effectiveness of existing interventions, we conducted a systematic review of the literature assessing the effect of Haemophilus influenzae type b (Hib) and pneumococcal (PC) conjugate vaccines on incidence, severe morbidity and mortality from childhood pneumonia.
We summarized cluster randomized controlled trials (cRCTs) and case-control studies of Hib conjugate vaccines and RCTs of 9- and 11-valent PC conjugate vaccines conducted in developing countries across outcome measures using standard meta-analysis methods. We used a set of standardized rules developed for the purpose of populating the LiST tool with required parameters to promote comparability across reviews of interventions against the major causes of childhood mortality. The estimates could be adjusted further to account for factors such as PC vaccine serotype content, PC serotype distribution and human immunodeficiency virus prevalence but this was not included as part of the LiST model approach.
The available evidence from published data points to a summary effect of the Hib conjugate vaccine on clinical pneumonia of 4%, on clinical severe pneumonia of 6% and on radiologically confirmed pneumonia of 18%. Respective effectiveness estimates for PC vaccines (all valent) on clinical pneumonia is 7%, clinical severe pneumonia is 7% and radiologically confirmed pneumonia is 26%.
The findings indicated that radiologically confirmed pneumonia, as a severe morbidity proxy for mortality, provided better estimates for the LiST model of effect of interventions on mortality reduction than did other outcomes evaluated. The LiST model will use this to estimate the pneumonia mortality reduction which might be observed when scaling up Hib and PC conjugate vaccination in the context of an overall package of child health interventions.
为了在 Lives Saved Tool(LiST)中填充现有干预措施有效性的参数,我们对评估乙型流感嗜血杆菌(Hib)和肺炎球菌(PC)结合疫苗对儿童肺炎发病率、严重发病率和死亡率影响的文献进行了系统评价。
我们总结了在发展中国家进行的 Hib 结合疫苗的群组随机对照试验(cRCT)和病例对照研究,以及 9 价和 11 价 PC 结合疫苗的 RCT,使用标准荟萃分析方法总结了这些研究的结果。我们使用了一套为将所需参数填充到 LiST 工具中而开发的标准化规则,以促进针对儿童死亡主要原因的干预措施的评价具有可比性。可以进一步调整这些估计值,以考虑 PC 疫苗血清型含量、PC 血清型分布和人类免疫缺陷病毒流行率等因素,但这不包括在 LiST 模型方法中。
已发表数据中的现有证据表明,Hib 结合疫苗对临床肺炎的总体效果为 4%,对临床严重肺炎的效果为 6%,对放射学确诊肺炎的效果为 18%。所有价次的 PC 疫苗(所有价次)对临床肺炎的有效性估计值为 7%,对临床严重肺炎的有效性估计值为 7%,对放射学确诊肺炎的有效性估计值为 26%。
这些发现表明,作为死亡率严重发病率的替代指标,放射学确诊肺炎为 LiST 模型提供了对干预措施降低死亡率效果的更好估计,优于其他评估结果。LiST 模型将使用这一指标来估计在儿童卫生综合一揽子干预措施的背景下,扩大 Hib 和 PC 结合疫苗接种时可能观察到的肺炎死亡率降低。